Sodium- and chloride-dependent glycine transporter 1

Sodium- and chloride-dependent glycine transporter 1, also known as glycine transporter 1, is a protein that in humans is encoded by the SLC6A9 gene which is promising therapeutic target for treatment of diabetes and obesity. ^[5][6][7][8]

SLC6A9
Identifiers
Aliases	SLC6A9, GLYT1, Glycine transporter 1, solute carrier family 6 member 9, GCENSG
External IDs	OMIM: 601019; MGI: 95760; HomoloGene: 5050; GeneCards: SLC6A9; OMA:SLC6A9 - orthologs
Gene location (Human) Chr. Chromosome 1 (human)[1] Band 1p34.1 Start 43,991,500 bp[1] End 44,031,467 bp[1]
Gene location (Mouse) Chr. Chromosome 4 (mouse)[2] Band 4 D1|4 53.62 cM Start 117,691,703 bp[2] End 117,732,395 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in C1 segment skin of leg skin of abdomen right adrenal gland stromal cell of endometrium left adrenal gland right adrenal cortex left adrenal cortex mucosa of transverse colon mucosa of esophagus Top expressed in neural layer of retina secondary oocyte retinal pigment epithelium fetal liver hematopoietic progenitor cell deep cerebellar nuclei primary oocyte zygote lumbar subsegment of spinal cord medulla oblongata dorsal tegmental nucleus More reference expression data BioGPS More reference expression data
Gene ontology Molecular function neurotransmitter:sodium symporter activity amino acid:sodium symporter activity glycine transmembrane transporter activity symporter activity glycine:sodium symporter activity transporter activity Cellular component integral component of membrane plasma membrane membrane presynapse integral component of plasma membrane postsynaptic density integral component of synaptic vesicle membrane asymmetric synapse hippocampal mossy fiber to CA3 synapse parallel fiber to Purkinje cell synapse integral component of postsynaptic membrane integral component of presynaptic membrane Biological process amino acid transmembrane transport neurotransmitter transport amino acid transport glycine secretion, neurotransmission glycine transport organic acid transmembrane transport transmembrane transport regulation of synaptic transmission, glycinergic Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 6536 14664 Ensembl ENSG00000196517 ENSMUSG00000028542 UniProt P48067 P28571 RefSeq (mRNA) NM_001024845 NM_001261380 NM_006934 NM_201649 NM_001328626 NM_001328627 NM_001328628 NM_001328629 NM_001328630 NM_008135 NM_001355175 NM_001369016 NM_001369017 RefSeq (protein) NP_001020016 NP_001248309 NP_001315555 NP_001315556 NP_001315557 NP_001315558 NP_001315559 NP_008865 NP_964012 NP_032161 NP_001342104 NP_001355945 NP_001355946 Location (UCSC) Chr 1: 43.99 – 44.03 Mb Chr 4: 117.69 – 117.73 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Selective inhibitors

Elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. Several drug candidates have reached clinical trials.^[9]

• ASP2535^[10]
• Bitopertin (RG1678), which has entered phase II trials for the treatment of schizophrenia^[11]
• Iclepertin (BI 425809) by Boehringer Ingelheim which is thought to improve cognitive impairment due to schizophrenia
• Org 25935 (Sch 900435)
• PF-03463275 (in phase II trial)
• Pesampator (PF-04958242) by Pfizer
• Sarcosine which is thought to improve cognitive impairment due to schizophrenia

Pathological mutations

Mutations of the gene may cause a severe metabolic disorder discovered in 2016 and called glycine encephalopathy with normal serum glycine (OMIM 617301), also known as GlyT1 encephalopathy.

See also

• Sodium:neurotransmitter symporter
• Solute carrier family